Skip Nav Destination
Issues
1 August 2016
-
Cover Image
Cover Image
The cover image shows a region (taken at approximately 200× magnification) of invasive prostatic adenocarcinoma glands infiltrating the prostatic stroma amongst benign/normal appearing prostatic glands/acini. Shown is an immunohistochemical stain against ERG (brown staining), which stains the tumor cell nuclei (indicated by arrows). Blue staining shows nuclei counterstained with hematoxylin. Note that benign endothelial cells are also positive for ERG (not specifically pointed out in the figure but apparent in the stroma as small nuclei with very strong intensity staining for ERG). Arrowheads show ERG positive adenocarcinoma cells partially replacing epithelium in benign acini/ducts. Four such partially involved benign glands are shown (denoted by numerals 1–4). These findings are supportive of the concept of retrograde colonization of benign/normal appearing acini/ducts by prostatic adenocarcinoma cells. It is expected that the tumor cells partially filling these acini/ducts may commonly undergo expansion over time to fully replace the benign epithelial cells. It is evident, therefore, that this spreading of invasive adenocarcinoma cells, which generally do have the appearance of malignant appearing cells on standard hematoxylin and eosin stained slides, into benign acini/ducts could lead to a misclassification of what is actually invasive adenocarcinoma as high grade PIN. See article by De Marzo et al. (beginning on page 648) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Commentary
Review: Molecular Pathogenesis of Premalignancy Series
Research Articles
Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk
Vered Stearns; Mary Jo Fackler; Sidra Hafeez; Zoila Lopez Bujanda; Robert T. Chatterton; Lisa K. Jacobs; Nagi F. Khouri; David Ivancic; Kara Kenney; Christina Shehata; Stacie C. Jeter; Judith A. Wolfman; Carola M. Zalles; Peng Huang; Seema A. Khan; Saraswati Sukumar
A Randomized Double-Blind Placebo-Controlled Phase IIB Trial of Curcumin in Oral Leukoplakia
Moni Abraham Kuriakose; Kunnambath Ramdas; Bindu Dey; Subramanya Iyer; Gunaseelan Rajan; Kalavathy K. Elango; Amritha Suresh; Divya Ravindran; Rajneesh R. Kumar; Prathiba R; Surya Ramachandran; Nisha Asok Kumar; Gigi Thomas; Thara Somanathan; Hiran K. Ravindran; Kannan Ranganathan; Sudhakar Babu Katakam; Shivashankar Parashuram; Vijayvel Jayaprakash; M. Radhakrishna Pillai
Effects of Black Raspberry Extract and Protocatechuic Acid on Carcinogen-DNA Adducts and Mutagenesis, and Oxidative Stress in Rat and Human Oral Cells
Joseph B. Guttenplan; Kun-Ming Chen; Yuan-Wan Sun; Wieslawa Kosinska; Ying Zhou; Seungjin (Agatha) Kim; Youngjae Sung; Krishne Gowda; Shantu Amin; Gary D. Stoner; Karam El-Bayoumy
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.